A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a ...

Shares of Merck & Co. Inc. MRK slipped 1.30% to $119.83 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.94% to 6,816.63 ...

The drugmaker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.

Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company ...

Merck reported breakthrough pivotal Phase 3 results for Keytruda-based combinations in renal cell carcinoma and ovarian cancer. The company also announced positive clinical trial data for a new HIV ...

Merck has increased its dividend for 14 consecutive years. Its 10-year dividend growth rate of 5.4% is only decent. Merck increased its revenue from $39.5 billion in FY 2015 to $64.2 billion in FY ...

Merck has an attractive yield and a long history of dividend growth.

Merck & Co. shares clocked seven straight sessions of gains, as the stock was up 0.2% at $124.1 on Tuesday. The global healthcare company gained 2% in the preceding six sessions.

In the latest close session, Merck (MRK) was down 1.95% at $121.41. This move lagged the S&P 500's daily gain of 0.04%. Meanwhile, the Dow experienced a drop of 0.15%, and the technology-dominated ...

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.